{"entity":{"id":"nct06616766","kind":"trial","name":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946","aka":[],"tldr":"A phase 1/2 trial of YH42946 in non-small-cell lung cancer, run by Yuhan Corporation, now recruiting.","summary":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate Safety, Tolerability, PK and Anti-tumor Activity of YH42946 is a phase 1/2 interventional study registered as NCT06616766 by Yuhan Corporation, with 201 participants planned, started 2024-10-02 and due to reach its primary completion in 2028-03-15. Interventions recorded: YH42946.","status":"recruiting","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT06616766","url":"https://clinicaltrials.gov/study/NCT06616766"}],"tags":["pipeline","ctgov-ingest"],"related":[],"cancers":["nsclc"],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT06616766","phase":"1/2","setting":"A Phase 1/2, Open-label, Multicenter, FIH Study to Evaluate the Safety, Tolerability, PK and Anti-tumor Activity of YH42946 in Patients With Locally Advanced or Metastatic Solid Tumors With HER2 Aberration and EGFR Exon 20 Insertion","sponsor":"Yuhan Corporation","enrolled":201,"outcomes":[]},"route":"/trials/nct06616766/","neighbours":{"cancer":[{"id":"nsclc","kind":"cancer","name":"Non-small-cell lung cancer","route":"/cancers/nsclc/"}]}}